Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets. But the focus among long-term investors is likely to be on another factor: the fact that Imbruvica, approved to treat several forms of lymphoma, generated $113 million, well ahead of the $83 million expected by those same forecasters.
No comments:
Post a Comment